艾加莫德治疗干燥综合征的2期随机对照概念验证研究
RHO研究是一项2期、随机、双盲、安慰剂对照、多中心概念验证研究,纳入34例成人干燥综合征患者,按2:1随机接受静脉艾加莫德10 mg/kg或安慰剂每周一次共24周。第24周时,艾加莫德组达到CRESS≥3项应答的比例数值上高于安慰剂组(45.5% vs 11.1%,治疗差异34.4%),cSTAR≥5分比例也数值上更高(54.5% vs 33.3%)。研究未进行正式统计假设检验,支持艾加莫德在干燥综合征中的概念验证,需进一步3期研究。
要点
- 艾加莫德组第24周CRESS≥3项应答率45.5%,安慰剂组11.1%,治疗差异34.4%。
- 艾加莫德组cSTAR≥5分比例54.5%,安慰剂组33.3%。
- 治疗中出现的不良事件均为1级或2级,艾加莫德组报告率87.0%,安慰剂组63.6%。
核心结论
- RHO研究数据支持艾加莫德在干燥综合征中的概念验证,值得进一步开展3期研究。
研究设计与样本
- 随机、双盲、安慰剂对照、2期、概念验证、多中心研究(RHO),参与者按2:1随机接受静脉艾加莫德10 mg/kg或安慰剂每周一次共24周。
- 共随机34例参与者(艾加莫德N=23,安慰剂N=11),其中31例纳入疗效分析。
- 主要结局为第24周达到CRESS 5项中≥3项应答的参与者比例。
- 未进行正式统计假设检验。
主要发现
- 第24周艾加莫德组CRESS≥3项应答比例为45.5%,安慰剂组为11.1%,治疗差异34.4%。
- 艾加莫德在5项CRESS条目中的4项上得分更高。
- 第24周艾加莫德组cSTAR≥5分比例为54.5%,安慰剂组为33.3%。
- 治疗中出现的不良事件在艾加莫德组报告率为87.0%,安慰剂组为63.6%,所有不良事件严重程度均为1级或2级。
关键数值与推荐
- 主要结局应答定义为CRESS 5项中≥3项应答,5项包括全身疾病活动度、患者报告症状、泪腺和唾液腺功能及血清学。
- 次要结局包括第24周cSTAR评分≥5分的比例。
临床怎么用
- 艾加莫德可能改善干燥综合征的复合应答指标,但当前证据为概念验证性质,尚未支持常规临床使用。
- 治疗中出现的不良事件以1-2级为主,安全性需在更大样本中进一步确认。
局限性
- 研究为2期概念验证研究,样本量小(随机34例,疗效分析31例),未进行正式统计假设检验。
- 结果均为数值上的差异,未报告统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the efficacy and safety of intravenous (IV) efgartigimod in adults with Sjögren's disease (SjD). METHODS: We conducted a randomised, double-blinded, placebo-controlled, phase 2, proof-of-concept multicentre study (hereafter referred to as RHO). Participants were randomised 2:1 to receive efgartigimod IV 10 mg/kg or placebo once weekly for 24 weeks. The primary outcome was the proportion of Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) responders on ≥3 of 5 items (systemic disease activity, patient-reported symptoms, tear and salivary gland function, and serology) at week 24. Secondary outcomes included the proportion with candidate Sjögren's Tool for Assessing Response (cSTAR) score ≥5 at week 24 and safety. No formal statistical hypothesis was tested. RESULTS: Thirty-four participants were randomised to efgartigimod (N = 23) or placebo (N = 11); 31 were included in the efficacy analysis. A numerically higher proportion of efgartigimod-treated participants responded to ≥3 items of CRESS at week 24 compared with placebo (45.5% vs 11.1%; treatment difference 34.4%). More specifically, efgartigimod scored higher on 4 of 5 CRESS items. Similarly, a numerically higher proportion of efgartigimod-treated participants scored ≥5 on the cSTAR at week 24 (efgartigimod, 54.5% vs placebo, 33.3%). Treatment-emergent adverse events were reported in 87.0% of efgartigimod-treated participants compared with 63.6% of those on placebo; all were grade 1 or 2 in severity. CONCLUSIONS: Data from the RHO study support proof of concept for efgartigimod in SjD. Further evaluation in a phase 3 study of efgartigimod in individuals with SjD is warranted. The trial was registered with ClinicalTrials.gov (NCT05817669).
引用
- Peene I, Verstappen GM, Arends S, et al. Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO). Ann Rheum Dis. 2026. PMID: 41997805. doi:10.1016/j.ard.2026.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。